Why Brand Owners Get Cited for CMO Failures

Under 21 CFR Part 111, a brand owner who outsources manufacturing to a contract manufacturer (CMO) retains full responsibility for GMP compliance. When the FDA inspects your CMO and finds violations, your name on the label is what appears in the Warning Letter.

The FDA's position is unambiguous: outsourcing production doesn't outsource liability. Choosing a CMO without verified GMP certification, without FDA registration, without quality agreements—that's not due diligence. It's undocumented risk that shows up in enforcement actions.

⚠️ FDA enforcement reality: In 2023, over 60% of dietary supplement Warning Letters cited inadequate supplier controls. "We trusted our CMO" is not a GMP control—it's a gap the FDA documents and cites.

The 10-point checklist below covers the minimum verifiable facts you need before signing with any CMO. Enter your name and email to access it free.

Free Checklist

Get the Full 10-Point Checklist

Enter your name and email. We'll send it to your inbox and unlock it here immediately. No spam—just the checklist and occasional GMP compliance resources.

No spam. Unsubscribe anytime.

Checklist unlocked. We've also sent a copy to your inbox.

The 10-Point CMO Due Diligence Checklist

Verify each of the following before signing with any contract manufacturer. These aren't aspirational—each item represents a documented FDA enforcement pattern.

FDA Enforcement

What Happens When Brand Owners Skip Due Diligence

These are not hypotheticals. Each pattern below appears repeatedly in FDA Warning Letters issued to brand owners who outsource manufacturing:

  • No quality agreement. FDA cites the brand owner directly—"no written quality agreement with contract manufacturer" appears verbatim in Warning Letters.
  • Unverified GMP status. A CMO's website badge doesn't satisfy FDA audit requirements. If you can't produce the certificate, you can't prove the claim.
  • No supplier qualification records. If your CMO can't show documented ingredient qualification, the FDA treats it as if no qualification occurred—regardless of how long you've been working together.
  • Missing change control notifications. Brands that discovered formulation changes after the fact—and had no change control clause—had no documented basis to show they maintained product oversight.

Need More Than a Checklist?

GMP Playbook builds the complete compliance documentation package—quality agreements, SOPs, specification sheets, and audit-ready records. Flat-rate pricing, no surprises.

Expanded
$5,000
More than 10 SKUs — one-time fee
  • Everything in Standard
  • Multi-SKU specification library
  • Extended SOP library (12+ SOPs)
  • Finished product templates per product line
  • Annual document review schedule
  • Priority delivery
Request a Consultation

Talk to Us About Your CMO Setup

If you've completed this checklist and found gaps—or if you're evaluating a new CMO and want to know where to focus—we can help. GMP Playbook builds the documentation infrastructure that makes your CMO relationship audit-ready.

Request a Free Consultation →